14 papers · ranked by Valyu relevance
Amanpreet Singh, Yong-Jie Xu, Eishi Noguchi
Hydroxyurea is a well-established inhibitor of ribonucleotide reductase that has a long history of scientific interest and clinical use for the treatment of neoplastic and non-neoplastic diseases. It is currently the staple drug for the management of sickle cell anemia and chronic myeloproliferative disorders. Due to…
Sunčica Kapor, Vladan Čokić, Juan F. Santibanez
Hydroxyurea (HU) is a water-soluble antiproliferative agent used for decades in neoplastic and nonneoplastic conditions. HU is considered an essential medicine because of its cytoreduction functions. HU is an antimetabolite that inhibits ribonucleotide reductase, which causes a depletion of the deoxyribonucleotide pool…
Federica Fogliazza, Martina Berzieri, Giulia Carbone, Davide Ciriaco + 2 more
Sickle cell disease (SCD) is the most common monogenic disorder worldwide and remains a major cause of morbidity and mortality. Sickle cell anemia (SCA), the homozygous HbSS genotype, represents the most severe and frequent form within the spectrum of SCD. Hydroxyurea (HU), a ribonucleotide reductase inhibitor…
Nirmani Yasara, Anuja Premawardhena, Sachith Mettananda
Background Hydroxyurea is one of the earliest drugs that showed promise in the management of haemoglobinopathies that include β-thalassaemia and sickle cell disease. Despite this, many aspects of hydroxyurea are either unknown or understudied; specifically, its usefulness in β-thalassaemia major and haemoglobin E…
Clarisse Lobo, Ana Cristina Silva-Pinto, Rodolfo Delfini Cançado
Despite sickle cell disease (SCD) being a well-recognized and highly prevalent condition identified early through neonatal screening programs, it represents a substantial public health challenge due to high morbidity and premature mortality rates. Hydroxyurea (HU) is the only available disease-modifying therapy for SCD…
Bijan Keikhaei, Homayon Yousefi, Mohammad Bahadoram
Sickle cell disease (SCD) is an autosomal recessive inherited hemoglobinopathy. This condition causes vaso occlusive phenomena and hemolysis due to the substitution of the amino acid valine for glutamic acid at the sixth position on the beta globin chain. As a resulta hemoglobin tetramer (alpha2/beta S2) known as…
Jean L. Santos, Priscila L. Bosquesi, Adélia E. Almeida, Chung Man Chin + 1 more
'Chung Man Chin' 'Eliana A. Varanda'] The hydroxyurea, a cytotoxic drug, is the mainly available therapeutical strategy for the treatment of sickle cell disease. This study aimed to evaluate the mutagenic and genotoxic potential of the hydroxyurea through the Salmonella/Microsome assay and micronucleus test in…
Nyabouk J. Gayluak, Sourav S. Roy, Ashley N. Plumb, Hemanth Mydugolam + 5 more
Chronic sickle cell disease (SCD) pain mechanisms remain critically understudied, even though more than 50% of patients develop this symptom as their disease progresses. Despite high face validity, there are critical gaps in transgenic SCD mouse model characterization and implementation that must be addressed in order…
Siana Nkya, Collin Nzunda, Emmanuel Saukiwa, Frida Kaywanga + 17 more
Sickle cell disease (SCD) continues to pose a significant public health challenge, particularly in sub-Saharan Africa. Despite its discovery over a century ago, the progress in developing and accessing effective interventions has been notably restricted. Currently, hydroxyurea stands as the primary drug in widespread…
Brendan E. Odigwe, Jesuloluwa S. Eyitayo, Celestine I. Odigwe, Homayoun Valafar
'Homayoun Valafar'] Hydroxyurea (HU) has been shown to be effective in alleviating the symptoms of Sickle Cell Anemia disease. While Hydroxyurea reduces the complications associated with Sickle Cell Anemia in some patients, others do not benefit from this drug and experience deleterious effects since it is also a…
Angelo D’Alessandro, S. Mehdi Nouraie, Yingze Zhang, Francesca Cendali + 7 more
Despite a wealth of exploratory plasma metabolomics studies in sickle cell disease (SCD), no study to date has evaluate a large and well phenotyped cohort to compare the primary erythrocyte metabolome of hemoglobin SS, SC and transfused AA red blood cells (RBCs) in vivo. The current study evaluates the RBC metabolome…
Tahereh Setayesh, Anifat Tijani, Harsimran Kaur, Shristi Khanal + 7 more
Sickle-hemoglobin-C (HbSC) sickle cell disease is characterized by RBC dehydration (xerocytosis), which promotes polymerization of HbS. HbSC causes substantial morbidity despite lower sickling potential than HbSS, suggesting a critical detrimental role of HbC in the disease pathophysiology. We derived HbCC mice by…
Min Lu, Sonja Billerbeck
The ability to precisely edit genomes by deleting or adding genetic information enables the study of biological functions and the building of efficient cell factories. In many unconventional yeasts – such as promising new hosts for cell factory design but also human pathogenic yeasts and food spoilers – this progress…
Ashleigh Burke, William Birmingham, Ying Zhuo, Bruna Zuculoto da Costa + 8 more
The COVID-19 pandemic highlights the urgent need for cost-effective processes to rapidly manufacture antiviral drugs at scale. Here we report a concise biocatalytic process for Molnupiravir, a nucleoside analogue currently in phase 3 clinical trials as an orally available treatment for SARS-CoV-2. Key to the success of…